Individuals with asymptomatic hemorrhaging infarction or subarachnoid hemorrhage after receiving endovascular treatment for ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...

The following is a summary of “Effect of sarcopenia on prognosis in patients with mild acute ischemic stroke: a prospective ...

The US Food and Drug Administration has approved the thrombolytic tenecteplase for the treatment of patients with acute ischemic stroke, manufacturer Genentech announced today. The approval is based ...

The usage of tenecteplase in patients with acute ischemic stroke was associated with similar effectiveness and safety ...